Registry of digestive tumors in Spain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the current state of digestive tumors in Spain, focusing on enhancing the quality of care and optimizing diagnosis and treatment. It will collect data on the epidemiological, biological, and clinical characteristics of digestive tumors diagnosed in patients aged 18 and older across various healthcare centers. The study will gather information from patients diagnosed before and after the study's initiation, and may also collect biological samples for translational research and identification of molecular markers. The goal is to generate scientific evidence that can improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and female patients ≥18 years old diagnosed with oesophageal cancer, gastric cancer, pancreatic cancer, hepatocarcinoma, gallbladder and bile duct cancer, cancer of the small intestine, appendix and gastrointestinal stroma, colorectal cancer, anal canal cancer or digestive hereditary cancer.
* Written informed consent available.

Exclusion Criteria:

* Patient for whom, for whatever reason, it is not possible to know or obtain the information necessary to complete the data collection base.

Where it's running

• Grupo de Tratamiento de los Tumores Digestivos (TTD)
  Madrid, Madrid, Spain Recruiting

Study contacts

• Study coordinator: Esther Mahillo, PhD
• Email: ttd@ttdgroup.org
• Phone: +34913788275

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A resource for collecting cancer data and biospecimens

  This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.

  Recruiting at 42 sites University of Nebraska · Greenwood Village, Colorado and 41 other locations · NCT02012699

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Tissue adhesive (Glubran®2) to reinforce pancreaticojejunostomy in soft pancreas

  This trial will test whether adding a tissue adhesive glue (Glubran®2) to the pancreatic-jejunal connection reduces postoperative pancreatic leaks in adults with a soft pancreas undergoing pancreaticoduodenectomy.

  Recruiting Minia University · Minya, Minya Governorate · NCT07155525

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer

  This study will test whether adding fruquintinib to FOLFIRI helps people with metastatic colorectal cancer who progressed after first-line FOLFOX plus bevacizumab.

  Recruiting at 14 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 13 other locations · NCT07011576

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.